Medically reviewed by a nuclear medicine physician specialising in radioligand therapy. Last reviewed: June 2026.
This article is about the PSMA track of lutetium therapy - specifically lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) for men with metastatic castration-resistant prostate cancer (mCRPC). If you have a neuroendocrine tumour and are considering Lu-177 DOTATATE, the fatigue patterns differ and a separate guide covers that track.
Fatigue is the most frequently reported side effect during Lu-177 PSMA therapy. In the phase 3 VISION trial - the study that led to FDA approval of this treatment - 43.1 percent of patients in the lutetium group reported fatigue as a treatment-emergent adverse event. It does not mean most men are bedridden. The majority describe heavy tiredness that peaks for several days after each infusion and then eases before the next cycle. Knowing when it hits helps you plan and recover.
This guide explains what causes fatigue during and after Lu-177 PSMA treatment, what to expect across each six-week cycle, and how to get your energy back during and after therapy.
Why Does Lu-177 PSMA Therapy Cause Fatigue?
Fatigue during radioligand therapy is not a sign that treatment is failing. It comes from several overlapping sources. Understanding those sources helps you and your care team find targeted solutions rather than guessing.
- The cancer itself. Advanced prostate cancer alters the body's metabolism and triggers chronic inflammation. These changes drain energy even before treatment begins.
- Anaemia. The lutetium isotope delivers low-level radiation to bone marrow as well as cancer lesions. This can slow red blood cell production. In the VISION trial, 31.8 percent of patients developed anaemia during treatment. Fewer red blood cells means less oxygen reaching your muscles, which directly causes tiredness and shortness of breath.
- Immune clearance work. When radiation damages cancer cells, the body works hard to remove the dead cells. This immune activity takes energy and contributes to the run-down feeling many men notice in the first week after each infusion.
- Hormone therapy effects. Most men receiving Lu-177 PSMA are also on androgen deprivation therapy (ADT). ADT is itself a well-documented cause of fatigue, muscle loss, and reduced stamina. The two effects can compound each other.
- Poor sleep. Anxiety before and after infusion days, frequent overnight urination, and bone pain can all disrupt sleep. Inadequate sleep makes every other cause of fatigue harder to recover from.
- Travel and logistics. For men travelling internationally for treatment - from the GCC, West Africa, South Asia, or further afield - long-haul flights, unfamiliar time zones, and the stress of being away from home add to physical exhaustion.
Research on cancer-related fatigue in prostate cancer confirms these factors rarely act alone. Most patients have multiple overlapping causes, which is why a single solution rarely fixes the problem on its own.
What Is the Fatigue Pattern Across Each Treatment Cycle?
Lu-177 PSMA therapy is given as an intravenous infusion every six weeks, for up to six cycles. The fatigue pattern across those cycles follows a similar path for most men.
- Days 1-2 after infusion: Many men feel relatively normal. Some notice mild improvement in symptoms as the treatment begins working on tumour cells.
- Days 3-10: This is the most commonly reported fatigue window. Tiredness tends to peak around days five to seven. Some men also experience a temporary increase in bone pain during this window - sometimes called a flare reaction - which adds to the sense of exhaustion.
- Days 10-28: Energy levels gradually recover for most patients. Blood counts may reach their lowest point during these weeks, so some men notice a secondary energy dip around weeks two to three as haemoglobin hits its nadir.
- Weeks four to six: Most men feel closer to their pre-infusion baseline before the next cycle begins. Use this time for gentle activity and nutrition focus.
After multiple cycles, some cumulative tiredness is normal. Your baseline energy may shift gradually lower by cycles four or five. This is expected and does not mean you are tolerating treatment poorly. Your oncologist will check blood counts before every infusion to confirm it is safe to proceed.
What Does the Evidence Say About Managing Fatigue?
A review of exercise interventions for cancer-related fatigue found that physical activity has the strongest evidence base of any approach - stronger than sleep medications, supplements, or rest alone. Here is what is known to help.
Gentle, consistent movement
The instinct when tired is to rest completely. Research suggests prolonged bed rest during treatment can backfire by causing muscle loss, which makes fatigue worse over time. Short walks - even 10 to 15 minutes after a meal - reduce fatigue severity and improve mood across multiple studies in cancer patients. You do not need to meet any gym target. The goal is to keep moving at whatever level your body allows that day.
If you were active before treatment, your oncology team may clear you for light resistance exercises such as gentle bodyweight movements or resistance bands. These help preserve muscle mass during the full treatment course.
Sleep quality and quantity
The Prostate Cancer Foundation notes that good sleep works alongside cancer treatment to reduce inflammation, stabilise mood, and support daily functioning. Men on ADT often experience disrupted sleep from hot flushes and frequent overnight urination. Strategies that help include keeping a consistent bedtime, keeping the bedroom cool, limiting screen use for an hour before bed, and asking your care team about managing night-time urinary frequency.
Cognitive behavioural therapy for insomnia (CBT-I) has strong evidence in cancer patients and does not carry the risks of sleeping pills. Ask your nurse or oncologist whether a referral is possible at your treatment centre.
Treating anaemia
If blood tests show a falling haemoglobin level, your care team may recommend dietary changes, iron supplements, or - in more significant cases - a blood transfusion or other medical intervention. Never self-supplement with iron without a blood test confirming deficiency. Your team monitors haemoglobin before every cycle specifically to catch and manage this early.
Nutrition and hydration between cycles
Treatment days require extra fluid intake because the kidneys clear lutetium from the body via urine. Staying well hydrated in the 24 hours before and after each infusion supports kidney function and may reduce the dull, heavy fatigue some men describe in the early post-infusion days. Small, frequent meals with adequate protein - eggs, fish, poultry, legumes, dairy - help maintain muscle mass during a period when appetite may be reduced by mild nausea or dry mouth.
Pacing your energy across the day
Schedule important tasks for times of day when your energy is naturally highest - often mid-morning for most people. Plan rest breaks into your schedule rather than waiting until you collapse. A simple activity diary kept for one week can reveal your personal energy pattern and help you plan your day better.
What Happens After the Final Cycle Ends?
Fatigue does not disappear the day treatment finishes. The weeks following your final Lu-177 PSMA infusion are often still challenging. Blood counts take weeks to normalise. The body continues to clear radiation-damaged cells. Some men find the six to eight weeks after the last cycle to be the most tiring stretch of the entire treatment course.
Most men report gradual improvement over two to three months after treatment ends. The factors linked to faster recovery include:
- How quickly haemoglobin levels return to a healthy range
- Whether gentle physical activity was maintained through and after treatment
- How well sleep was managed during the treatment course
- Whether the cancer is responding - men whose disease responds often feel substantially better as tumour burden decreases and the survival benefits documented in the VISION trial improve daily life
If you want to structure your recovery period with evidence-based approaches, the article on integrative therapies and lifestyle support during Lu-177 PSMA treatment covers exercise, nutrition, and complementary approaches based on research.
Side Effects That Interact with Fatigue
Fatigue usually comes with other side effects. Several common side effects from the VISION trial interact with it. Dry mouth (xerostomia) affects around 38 percent of patients on lutetium Lu-177 vipivotide tetraxetan and makes eating and staying hydrated harder, which worsens tiredness. Nausea in the first 24 to 48 hours after infusion is common and reduces food and fluid intake during the window when your body most needs both. Your care team will typically prescribe anti-nausea medication for that period. Controlling nausea well helps you recover energy.
The full-length guide on real-world side effects of Lu-177 PSMA therapy and how doctors manage them covers the complete picture, including bone marrow thresholds, when dose adjustments are considered, and how teams balance efficacy against tolerability.
The Week Immediately After Each Infusion
The seven days after your Lu-177 PSMA infusion are when fatigue and other early side effects are most likely to be noticeable. Radiation safety precautions - such as limiting close contact with pregnant women and young children and using separate bathroom facilities where possible - also apply during this first week. Planning and managing these steps is hard when you are tired. Preparing in advance - knowing who will help at home, what meals will be available, and what activities to scale back - helps. The article on what happens in the week after your Lu-177 PSMA infusion covers both the practical radiation safety steps and the question of returning to work or normal activities.
When to Tell Your Care Team About Your Fatigue
Most fatigue during Lu-177 PSMA treatment is predictable and manageable. But some symptoms need prompt attention. Contact your care team without waiting for the next scheduled appointment if:
- You feel breathless at rest or with minimal effort - this may signal significant anaemia
- Fatigue is severe enough to prevent you from getting out of bed or looking after yourself
- Fatigue worsens between cycles rather than easing as expected
- New or worsening bone pain accompanies the tiredness
- You notice easy bruising or unexplained bleeding, which may indicate a low platelet count
Blood tests before every cycle are the main safety net. Your oncologist tracks haemoglobin, platelets, white cell count, and kidney function at each check-in. If counts fall below a safe threshold, the next infusion may be delayed or the dose adjusted - not because treatment is failing, but to protect your bone marrow and allow safe continuation of therapy.
When to Talk to Your Doctor
Speak to your oncologist or specialist nurse at your next appointment if fatigue is affecting your daily life, your sleep, or your ability to eat and stay hydrated. Ask about your most recent haemoglobin level and whether it may be contributing to how tired you feel. Ask whether a referral to a physiotherapist or oncology dietitian is available at your treatment centre. If you are travelling to India for treatment and returning home between cycles, make sure your local oncologist has your most recent blood results so they can monitor your counts during the gap.
If you are still weighing whether Lu-177 PSMA therapy is the right next step for your situation, or if you want a specialist to review your PSMA-PET scan and eligibility markers, you can send your scan results for a free eligibility review through HealthUnwired. If lutetium Lu-177 vipivotide tetraxetan turns out not to be the right fit, a second opinion on alternative options is also available.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Will fatigue from Lu-177 PSMA therapy stop me from doing everyday tasks?
For most men, fatigue during Lu-177 PSMA treatment is mild to moderate rather than severe. In the VISION trial, fatigue was the most commonly reported side effect but rarely caused patients to stop treatment. Many men continue light daily activities such as walking, cooking, and socialising throughout their treatment course. The days around the peak fatigue window - typically days three to seven after each infusion - are when you may want to plan less demanding tasks. Tell your care team if fatigue is preventing you from caring for yourself or moving around your home.
Is Lu-177 PSMA fatigue different from chemotherapy fatigue?
The two share similarities but tend to differ in timing and character. Chemotherapy fatigue - particularly with docetaxel - can be intense and closely tied to the drug cycle, sometimes reaching a level many men describe as collapse. Fatigue from lutetium Lu-177 vipivotide tetraxetan is generally described as milder and more gradual, developing over several days after each infusion. However, many men receiving Lu-177 PSMA have already had chemotherapy, which means they may be starting treatment with some residual baseline fatigue. Your care team considers this when planning supportive care.
Can I take vitamins or supplements to help with fatigue during Lu-177 PSMA therapy?
Some supplements can interfere with cancer treatment or affect kidney function, so always ask your oncologist before starting anything new. Iron supplements are only helpful if blood tests confirm iron-deficiency anaemia - excess iron does not boost energy and can cause other problems. Vitamin D is often low in men with prostate cancer, especially those on hormone therapy, but your doctor needs to check your blood level before recommending a dose. Energy supplements sold in health stores are generally not studied in this setting and some contain ingredients that may interact with cancer medications.
Will my energy come back after the Lu-177 PSMA treatment course ends?
Most men report a gradual return of energy over the two to three months following their final infusion. Recovery tends to be fastest in men whose haemoglobin levels return to a healthy range quickly and who maintain some physical activity throughout treatment. A smaller number of men notice reduced stamina for up to six months, particularly if they experienced significant anaemia or if they are managing ongoing fatigue from androgen deprivation therapy. Tracking your blood counts and staying in touch with your oncologist through the recovery period helps identify anything that needs active treatment.
Can I exercise during Lu-177 PSMA treatment if I have bone metastases?
Gentle exercise is generally encouraged, even with bone metastases, but the type and intensity should be guided by your oncologist and ideally by a physiotherapist familiar with bone metastatic disease. Low-impact activities such as walking and light resistance exercise are typically safe and have evidence supporting their benefit on fatigue and muscle preservation. High-impact activities that place stress on the spine or weight-bearing bones require more careful assessment. Always tell your team about any new or worsening bone pain before starting or changing an exercise routine.
Does the number of Lu-177 PSMA cycles affect how severe fatigue becomes?
Some cumulative tiredness is common as cycles progress. Many men find that cycles one and two are easier to recover from than cycles four and five, as small effects on bone marrow and energy reserves can add up over time. However, for some men - particularly those whose disease is responding well and whose tumour burden is decreasing - energy actually improves over the course of treatment as the cancer itself is a major contributor to fatigue. Blood count monitoring before every cycle is the main tool for detecting when cumulative effects need to be managed with a dose delay or adjustment.